Becton Dickinson and Co (BDX.N)
247.75USD
17 Jul 2018
$2.62 (+1.07%)
$245.13
$245.35
$248.36
$244.77
158,453
330,498
$248.36
$191.53
About
Overall
| Beta: | 1.14 |
| Market Cap(Mil.): | $66,199.26 |
| Shares Outstanding(Mil.): | 267.20 |
| Dividend: | 0.75 |
| Yield (%): | 1.21 |
Financials
| BDX.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 332.23 | 41.57 | 33.15 |
| EPS (TTM): | 0.75 | -- | -- |
| ROI: | 0.92 | 14.53 | 13.23 |
| ROE: | 1.21 | 17.68 | 15.27 |
U.S. investigates bloodstream infections for link to heparin syringes
SHANGHAI/CHICAGO Health agencies are investigating an outbreak of bloodstream infections in children from four U.S. states that may be linked to heparin and saline syringes made by Becton Dickinson and Co, the agencies told Reuters. The U.S. Centers for Disease Control and Prevention has confirmed 14 cases of bloodstream infections in children caused by the same strain of the Serratia marcescens bacterium, the agency's lead investigator on the outbreak said in a telephone interview.
U.S. investigates bloodstream infections for link to heparin syringes
* 14 children in 4 states have confirmed bloodstream infections
BRIEF-Becton Dickinson Reports Q2 Loss Per Share $0.19
* BD ANNOUNCES RESULTS FOR 2018 SECOND FISCAL QUARTER; RAISES FISCAL 2018 GUIDANCE
BRIEF-Becton Dickinson Files For Potential Mixed Shelf Offering
* BECTON DICKINSON AND CO FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2HvryvV) Further company coverage:
BRIEF-Becton Dickinson Updates Instructions for Use for Certain BD Vacutainer Blood Collection Tubes
* BECAME AWARE OF CONCERNS ABOUT INACCURATE LEAD TEST RESULTS FROM MAGELLAN DIAGNOSTICS LEADCARE TESTING SYSTEMS
BRIEF-Becton, Dickinson To Divest Remaining Investment In Vyaire Medical
* BD TO DIVEST REMAINING INVESTMENT IN VYAIRE MEDICAL TO FUNDS MANAGED BY APAX PARTNERS
BRIEF-Becton Dickinson Launches Circulating Cell-Free DNA Blood Collection Tube in Western Europe
* BD LAUNCHES CIRCULATING CELL-FREE DNA BLOOD COLLECTION TUBE FOR CANCER AND NON-INVASIVE PRENATAL TESTING APPLICATIONS
BRIEF-Becton Dickinson Files For Offering EUR 300 Mln Add. 0.368% Notes
* BECTON DICKINSON AND CO FILES FOR OFFERING EUR 300 MILLION AGGREGATE PRINCIPAL AMOUNT OF ADDITIONAL 0.368% NOTES DUE 2019 - SEC FILING
BRIEF-Becton Dickinson Says Received Pre-Market Approval From FDA For BD Onclarity HPV Assay
* FDA APPROVES NEW HPV TEST THAT DETECTS AND IDENTIFIES HPV GENOTYPES THAT PUT WOMEN AT HIGH RISK FOR CERVICAL CANCER Source text for Eikon: Further company coverage:
BRIEF-Becton Dickinson Q1 Loss Per Share $0.76
* BD ANNOUNCES RESULTS FOR 2018 FIRST FISCAL QUARTER; PROVIDES FISCAL 2018 GUIDANCE UPDATED FOR INCLUSION OF BARD
Competitors
| Price | Chg | |
|---|---|---|
| Baxter International Inc (BAX.N) | $74.75 | +0.74 |
| Stryker Corporation (SYK.N) | $176.11 | +2.69 |
| Boston Scientific Corporation (BSX.N) | $33.95 | +0.80 |
| C R Bard Inc (BCR.N) | -- | -- |
| Hologic, Inc. (HOLX.OQ) | $41.50 | -- |
| Quidel Corporation (QDEL.OQ) | $70.95 | -- |
| Abbott Laboratories (ABT.N) | $62.80 | +1.02 |
| Gen-Probe Incorporated (GPRO.OQ) | $6.51 | -- |
Estimates